SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-010226
Filing Date
2024-01-18
Accepted
2024-01-18 16:26:28
Documents
12
Period of Report
2024-01-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d700531d8k.htm   iXBRL 8-K 22746
  Complete submission text file 0001193125-24-010226.txt   147299

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syre-20240116.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syre-20240116_lab.xml EX-101.LAB 18757
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syre-20240116_pre.xml EX-101.PRE 11728
6 EXTRACTED XBRL INSTANCE DOCUMENT d700531d8k_htm.xml XML 3516
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 24542161
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)